Press ReleaseCOUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Secures FDA Orphan Drug Designation for CNP-104 in Primary Biliary Cholangitis Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer Press Release / lsc-webmaster
